Dorothee
Dorothee Altemir, Tacoignieres FR
Patent application number | Description | Published |
---|---|---|
20140286907 | TRANSIENT EXPRESSION VECTORS, PREPARATION AND USES THEREOF - The present invention describes a recombinant retroviral vector which cannot by itself achieve complete reverse transcription as well as its uses, in particular for transiently transferring in vitro, ex vivo or in vivo at least one ribonucleic acid sequence of interest in a cell. Such a transient transgene expression is of interest in the context of research, therapy and more generally in the field of biotechnology. | 09-25-2014 |
Dorothee Bardiot, Leuven BE
Patent application number | Description | Published |
---|---|---|
20140213586 | VIRAL REPLICATION INHIBITORS - The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds. | 07-31-2014 |
20140296272 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS - The present invention relates to a series of compounds having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutic amount of such compounds, optionally combined with one or more other drugs having anti-viral activity. | 10-02-2014 |
Dorothee Cheuret, Paris FR
Patent application number | Description | Published |
---|---|---|
20130165422 | HEXAFLUOROISOPROPYL CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION - The disclosure relates to hexafluoroisopropyl carbamate derivatives of general formula (I): | 06-27-2013 |
Dorothee Debavelaere-Callens, Sameon FR
Patent application number | Description | Published |
---|---|---|
20110314920 | DEVICE AND METHOD FOR STUDYING A STUDY AREA BY MEANS OF AN ACOUSTIC WAVE - A device includes a substrate | 12-29-2011 |
Dorothee Duluc, Dallas, TX US
Patent application number | Description | Published |
---|---|---|
20130017151 | SUBSETS OF ANTIGEN-PRESENTING CELLS (APCs) IN THE HUMAN VAGINA AND THEIR DISTINCT FUNCTIONS - Compositions and methods for generating dendritic cell (DC)-targeting vaccines against vaginal infections, including but not limited to sexually transmitted diseases, are disclosed herein. The present invention reports the isolation of at least four major subsets of myeloid-originated antigen-presenting cells (APCs) that possess distinct phenotypes and functions in directing immune responses, namely, Langerhans cells (LCs: E-cadherin | 01-17-2013 |
Dorothee Foernzler, Lenzburg DE
Patent application number | Description | Published |
---|---|---|
20090286234 | IL10 SNP ASSOCIATED WITH ACUTE REJECTION - The present invention concerns a method for the prediction of acute renal transplant rejection by detecting a poly-morphism in the promoter region of the IL 10 gene, optionally in combination with polymorphisms of the MDR1 and IMPDH2 genes which were found to be associated with this disease. | 11-19-2009 |
20090286235 | Mdr1 Snp in Acute Rejection - The present invention concerns a method for the prediction of acute renal transplant rejection by detecting a polymorphism in exon 26 of the MDR1 gene, optionally in combination with polymorphisms of the IMPDH2 and IL 10 genes which were found to be associated with this disease. | 11-19-2009 |
Dorothee Foernzler, Lenzburg CH
Patent application number | Description | Published |
---|---|---|
20100092947 | Impdh2 snp associated with acute rejection - The present invention concerns a method for the prediction of acute renal transplant rejection by detecting a polymorphism in intron 7 of the IMPDH2 gene, optionally in combination with polymorphisms of the MDR1 and IL 10 genes which were found to be associated with this disease. | 04-15-2010 |
20110182892 | Methods to identify responsive patients - The present invention provides methods and kits for improving the progression-free survival of a patient suffering from gastrointestinal cancer and for assessing the sensitivity or responsiveness of the patient to treatment comprising bevacizumab. | 07-28-2011 |
20120195858 | RESPONSIVENESS TO ANGIOGENESIS INHIBITORS - The present invention relates to methods for improving the overall survival of a patient suffering from a malignant disease or a disease involving physiological and pathological angiogenesis by treatment with an angiogenesis inhibitor, such as bevacizumab, by determining the presence of one or more variant alleles of the vascular endothelial growth factor receptor 1 (VEGFR-1) gene. The present invention further provides methods for improving the progression-free survival of a patient suffering from a malignant disease or a disease involving physiological and pathological angiogenesis by treatment with an angiogenesis inhibitor, such as bevacizumab, by determining the presence of one or more variant alleles of the VEGFR-1 gene. The present invention also provides for methods for assessing the responsiveness of a patient to an angiogenesis inhibitor by determining the presence of one or more variant alleles of the VEGFR-1 gene. | 08-02-2012 |
20130108626 | BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF PANCREATIC CANCER | 05-02-2013 |
20130121999 | BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER - The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels of patients diagnosed with breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer. In particular, the present invention provides methods of improving the treatment effect, wherein the treatment effect is the progression-free survival of the patient. The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels in patients diagnosed with breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer. | 05-16-2013 |
20130171134 | NEUROPILIN AS A BIOMARKER FOR BEVACIZUMAB COMBINATION THERAPIES - The present invention provides methods for improving treatment effect in a patient suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”), by treatment with bevacizumab (Avastin®) in combination with a chemotherapy regimen by determining the expression level of neuropilin relative to a control level determined in patients suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”). The improved treatment effect may be improved overall survival or improved progression free survival. The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level of neuropilin relative to a control level determined in patients suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”). | 07-04-2013 |
20130177554 | NEUROPILIN AS A BIOMARKER FOR BEVACIZUMAB COMBINATION THERAPIES - The present invention provides methods for improving treatment effect in a patient suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”), by treatment with bevacizumab (Avastin®) in combination with a chemotherapy regimen by determining the expression level of neuropilin relative to a control level determined in patients suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”). The improved treatment effect may be improved overall survival or improved progression free survival. The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level of neuropilin relative to a control level determined in patients suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”). | 07-11-2013 |
20130183301 | BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF PANCREATIC CANCER - The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from pancreatic cancer, in particular metastatic pancreatic cancer by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels of patients diagnosed with pancreatic cancer, in particular metastatic pancreatic cancer. In particular, the present invention provides methods of improving the treatment effect, wherein the treatment effect is the overall survival and/or progression-free survival of the patient. The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels in patients diagnosed with pancreatic cancer, in particular metastatic pancreatic cancer. | 07-18-2013 |
20130183302 | BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER - The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels of patients diagnosed with breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer. In particular, the present invention provides methods of improving the treatment effect, wherein the treatment effect is the progression-free survival of the patient. The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels in patients diagnosed with breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer. | 07-18-2013 |
20130183303 | BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER - The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels of patients diagnosed with breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer. In particular, the present invention provides methods of improving the treatment effect, wherein the treatment effect is the progression-free survival of the patient. The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels in patients diagnosed with breast cancer, in particular locally advanced, recurrent or metastatic HER-2 negative breast cancer. | 07-18-2013 |
20130183304 | NEUROPILIN AS A BIOMARKER FOR BEVACIZUMAB COMBINATION THERAPIES - The present invention provides methods for improving treatment effect in a patient suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”), by treatment with bevacizumab (Avastin®) in combination with a chemotherapy regimen by determining the expression level of neuropilin relative to a control level determined in patients suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”). The improved treatment effect may be improved overall survival or improved progression free survival. The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level of neuropilin relative to a control level determined in patients suffering from gastric cancer, in particular, adenocarcinoma of the stomach or gastro-esophageal junction (“GEJ”). | 07-18-2013 |
20130195857 | BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF PANCREATIC CANCER - The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from pancreatic cancer, in particular metastatic pancreatic cancer by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels of patients diagnosed with pancreatic cancer, in particular metastatic pancreatic cancer. In particular, the present invention provides methods of improving the treatment effect, wherein the treatment effect is the overall and/or progression-free survival of the patient. The present invention further provides methods for assessing the sensitivity or responsiveness of a pancreatic cancer patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, using similar methods. | 08-01-2013 |
20140099302 | METHODS TO IDENTIFY RESPONSIVE PATIENTS - The present invention provides methods and kits for improving the progression-free survival of a patient suffering from gastrointestinal cancer and for assessing the sensitivity or responsiveness of the patient to treatment comprising bevacizumab. | 04-10-2014 |
20140302019 | BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF PANCREATIC CANCER - The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from pancreatic cancer, in particular metastatic pancreatic cancer by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels of patients diagnosed with pancreatic cancer, in particular metastatic pancreatic cancer. In particular, the present invention provides methods of improving the treatment effect, wherein the treatment effect is the overall survival and/or progression-free survival of the patient. The present invention further provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of one or more of VEGFA, VEGFR2 and PLGF relative to control levels in patients diagnosed with pancreatic cancer, in particular metastatic pancreatic cancer. | 10-09-2014 |
Dorothee Gierschner, Teningen DE
Patent application number | Description | Published |
---|---|---|
20090041789 | Monoclonal Antibodies and Single Chain Antibody Fragments Against Cell-Surface Prostate Specific Membrane Antigen - Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody. | 02-12-2009 |
20120231024 | MONOCLONAL ANTIBODIES AND SINGLE CHAIN ANTIBODY FRAGMENTS AGAINST CELL-SURFACE PROSTATE SPECIFIC MEMBRANE ANTIGEN AS DIAGNOSTIC AND THERAPEUTIC TOOLS FOR PROSTATE CANCER - Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody. | 09-13-2012 |
20140155583 | MONOCLONAL ANTIBODIES AND SINGLE CHAIN ANTIBODY FRAGMENTS AGAINST CELL-SURFACE PROSTATE SPECIFIC MEMBRANE ANTIGEN - Isolated monoclonal antibodies or an antigen binding portion thereof which bind to prostate specific membrane antigen in its native form occurring on the surface of tumor cells characterized in that it is linked to a label or a cytotoxic agent or constructed as a part of a bispecific antibody or a recombinant diabody. | 06-05-2014 |
Dorothee Guenaltay, Emmerting DE
Patent application number | Description | Published |
---|---|---|
20140251139 | METHOD FOR PROCESSING WASTEWATER AND EXHAUST GAS CONDENSATES FROM THE POLYMERIZATION OF VINYL ACETATE AND ETHYLENE IN AN AQUEOUS MEDIUM - A method for processing wastewater and exhaust gas condensates from the polymerization of vinyl acetate and ethylene and optionally other comonomers in an aqueous medium by suspension or emulsion polymerization employs relieving pressure after completion of the polymerization of the polymerization batch and discharging the polymer dispersion. During the relieving, the gaseous phase is removed by means of a compressor. Optionally, the gaseous phase occurring during stripping is removed by the compressor and cooled by one or more heat exchangers before entry into the compressor. The liquid phases occurring in the compressor and optionally in the heat exchanger are separated from the gaseous phase and the liquid phases are given to a rectification column, and separated into a vinyl acetate monomer phase and a wastewater phase, and the vinyl acetate monomer phase is resupplied to polymerization. | 09-11-2014 |
Dorothee Heidemeter, Dusseldorf DE
Patent application number | Description | Published |
---|---|---|
20080220034 | Antiadhesive Polymers for Prevention of Adhesion of Microorganisms to Textiles and for Prevention of Laundry Odor - Textile treatment agents and/or capsules comprising a polymer having antiadhesive action against microorganisms which adhere to a textile substrate, methods of treating textile substrates therewith and the textile so treated, wherein the polymer comprises a polymeric structural element selected from the group consisting of polyesters, polysaccharides, polyethers, polyurethanes, polyureas, polyamides, and heteropolymers thereof. | 09-11-2008 |
Dorothee Heisenberg, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20130218024 | Interventional In-Situ Image-Guidance by Fusing Ultrasound and Video - An augmentation device for an imaging system has a bracket structured to be attachable to an imaging component, and a projector attached to the bracket. The projector is arranged and configured to project an image onto a surface in conjunction with imaging by the imaging system. A system for image-guided surgery has an imaging system, and a projector configured to project an image or pattern onto a region of interest during imaging by the imaging system. A capsule imaging device has an imaging system, and a local sensor system. The local sensor system provides information to reconstruct positions of the capsule endoscope free from external monitoring equipment. | 08-22-2013 |
Dorothee Henras, Le Chesnay FR
Patent application number | Description | Published |
---|---|---|
20120189089 | METHOD OF OPERATING A PRESSURIZED-WATER NUCLEAR REACTOR ALLOWING SAME TO PASS FROM A PLUTONIUM-EQUILIBRIUM CYCLE TO A URANIUM- EQUILIBRIUM CYCLE AND CORRESPONDING NUCLEAR FUEL ASSEMBLY - A method is provided for operating a nuclear reactor. The method includes operating the nuclear reactor for at least one plutonium equilibrium cycle during which the core contains plutonium-equilibrium nuclear fuel assemblies; subsequently, operating the reactor for transition cycles, at least some of the plutonium-equilibrium nuclear fuel assemblies being progressively replaced with transition nuclear fuel assemblies and then with uranium-equilibrium nuclear fuel assemblies; and then operating the nuclear reactor for at least one uranium equilibrium cycle. | 07-26-2012 |
Dorothee Henras, Le Chesney FR
Patent application number | Description | Published |
---|---|---|
20120163525 | METHOD OF OPERATING A PRESSURIZED-WATER NUCLEAR REACTOR FOR REACHING A PLUTONIUM EQUILIBRIUM CYCLE - A method is provided for operating a nuclear reactor. The method includes operating the nuclear reactor for an initial cycle during which a core contains initial nuclear fuel assemblies; then operating the nuclear reactor for transition cycles, at least some of the initial nuclear fuel assemblies being progressively replaced, during the replacement steps preceding the transition cycles, with transition nuclear fuel assemblies or with plutonium-equilibrium nuclear fuel assemblies; and then operating the nuclear reactor for at least one plutonium equilibrium cycle during which the core contains only plutonium-equilibrium nuclear fuel assemblies. | 06-28-2012 |
Dorothee Kloepping, Schlangen DE
Patent application number | Description | Published |
---|---|---|
20120064202 | METHOD AND DEVICE FOR PRODUCING PUREED FOOD - A method, device, and knife system for producing purëed, cooked foodstuffs from piece-form raw material. The method includes pre-chopping of the piece-form raw material in a pre-chopping unit, cooking of the pre-chopped raw material in a cooking plant, and final processing of the cooked product in a final-processing unit. Before cooking, the piece-form raw material is cut into small pieces by the pre-chopping unit such that a pumpable mass is produced from the piece-form raw material. | 03-15-2012 |
Dorothee Lang, Pinneberg DE
Patent application number | Description | Published |
---|---|---|
20090139519 | OXYGEN SUPPLY SYSTEM FOR GENERATING OXYGEN FROM CABIN AIR IN AN AIRCRAFT - An oxygen supply system is provided for generating oxygen from cabin air in an aircraft. The oxygen supply system exhibits a modular cabin unit with an oxygen port and a decentralized oxygen supply unit with an oxygen outlet, and the decentralized oxygen supply unit is set up in the modular cabin unit. The decentralized oxygen supply unit is set up to generate oxygen-enriched air from the cabin air by means of electrical power, and the oxygen-enriched air can be provided to the oxygen port of the modular cabin unit via the oxygen outlet. | 06-04-2009 |
20120325217 | OXYGEN MODULE - The present disclosure provides a flexible oxygen supply system which can easily be adapted to different seat layouts and which is significantly improved with regard to test and maintenance possibilities. An oxygen module according to the present disclosure generally comprises an oxygen source, a mask and a tube between the oxygen source and a mask. The oxygen module further comprises fastening elements for fastening in a supply duct of an aircraft, and a locking element by means of which the cover of the oxygen module can be locked. | 12-27-2012 |
20130005231 | INCOMING AIR SUPPLY SYSTEM FOR PASSENGERS IN AIRCRAFT - Incoming air system for passengers in a passenger compartment, in which the supply duct does not have to be reconstructed if the seat configuration is altered. This is provided by means of an air distribution element, which is continuous in the longitudinal direction of the aircraft and which comprises openings at defined positions which are adapted to possible seat layouts. Openings which are not required are sealed, for example by means of a selection element which encloses the air distribution element and is slitted on one side. | 01-03-2013 |
Dorothee Le Garrec, Montreal CA
Patent application number | Description | Published |
---|---|---|
20090130183 | Bilayer Composition for the Sustained Release of Acetaminophen and Tramadol - The invention relates to a bilayer composition for the delivery of acetaminophen and tramadol over at least a twelve hour period following initial administration. A single administration of the bilayer composition can provide analgesia starting in less than half an hour to about one hour after initial administration with a duration of at least twelve hours after initial administration. | 05-21-2009 |
20090258071 | COMPOSITIONS AND METHODS FOR PH TARGETED DRUG DELIVERY - The invention provides compositions and methods for the targeted, in particular, pH targeted, delivery of pharmaceutically active agents in mammals. The compositions comprise pH sensitive diblock copolymers, which permit the release of the pharmaceutically active agent when exposed to an environment having a particular pH. The compositions are particularly useful for the oral delivery of water insoluble pharmaceutically active agents. | 10-15-2009 |
20130039864 | Non-Intravenous Dosage Form Comprising Solid Formulation of Liquid Biologically Active Agent and Uses Thereof - The disclosure relates to a non-intravenous dosage for administration of a liquid biologically active agent. The dosage form contains a solid formulation of the liquid biologically active agent, e.g. propofol, in intimate association with at least one stabilizing agent, e.g. an amphiphilic polymer or surfactant. A liquid biologically active agent is converted to a solid product, e.g. a powder, that can be easily incorporated into a number of different non-intravenous dosage forms. Upon hydration, a nanodispersion or micelle loaded with the active agent is formed. The dosage form can provide a non-intravenous route of administration for active agents that are typically only administered intravenously. Methods, uses, kits and commercial packages related to the non-intravenous dosage form are also disclosed. | 02-14-2013 |
20140323587 | SOLID FORMULATIONS OF LIQUID BIOLOGICALLY ACTIVE AGENTS - The instant invention relates to a solid product comprising a liquid biologically active agent which is intimately associated to a stabilizing agent; particularly a solid product that can be reconstituted to a clear, stable, stabilized nanodispersion or loaded micelles comprising a polymer as a stabilizing agent and a liquid, preferably water immiscible, biologically active agent. The instant invention is further directed toward a process for the production of the above solid product; particularly to micelles or nanodispersions produced by hydration of a cake or powder of the solid product, produced via an effective treatment of a stabilized solution comprising for example a polymer as a stabilizing agent, such as an amphiphilic block copolymer or a small molecular weight surfactant, loaded with a liquid biologically active agent, such as propofol, an optional additive, and a suitable solvent. | 10-30-2014 |
Dorothee Maroserro, Paris FR
Patent application number | Description | Published |
---|---|---|
20090299212 | System and Method for Analyzing Progress of Labor and Preterm Labor - Systems and methods for monitoring uterus contraction activity and progress of labor. The system of the subject invention can comprises (1) a plurality of sensors; (2) an amplifying/filtering means; (3) a computing means; and (4) a graphical user interface. Accurate clinical data, which can be extracted and provided to the user in real-time using the system of the invention, include without limitation, progress of labor, prediction and monitoring of preterm labor, and intrauterine pressure prediction. In a preferred embodiment, the system of the invention includes an intelligence means, such as a neural network system, to analyze and interpret clinical data for use in clinical diagnosis as well as delivery strategy. | 12-03-2009 |
20120238894 | System and Method for Analyzing Progress of Labor and Preterm Labor - Systems and methods for monitoring uterus contraction activity and progress of labor. The system of the subject invention can comprises (1) a plurality of sensors; (2) an amplifying/filtering means; (3) a computing means; and (4) a graphical user interface. Accurate clinical data, which can be extracted and provided to the user in real-time using the system of the invention, include without limitation, progress of labor, prediction and monitoring of preterm labor, and intrauterine pressure prediction. In a preferred embodiment, the system of the invention includes an intelligence means, such as a neural network system, to analyze and interpret clinical data for use in clinical diagnosis as well as delivery strategy. | 09-20-2012 |
Dorothee Marossero, Coogee AU
Patent application number | Description | Published |
---|---|---|
20120071744 | Sensor Interface System - A sensor interface system for providing a connection between at least one sensor and a maternal-fetal monitor, wherein the interface system converts electrical muscle activity captured by the sensor(s) into uterine activity data signals for use by the maternal-fetal monitor. The sensor interface system of the invention preferably includes a conversion means for converting the signals from the sensor(s) into signals similar to those produced by a tocodynamometer. | 03-22-2012 |
Dorothee Marossero, Gainesville, FL US
Patent application number | Description | Published |
---|---|---|
20110112440 | Electrode Interface System - An electrode interface system for providing a connection between at least one electrode and a maternal-fetal monitor, wherein the interface system converts electrical muscle activity captured by the electrode(s) into uterine activity data signals for use by the maternal-fetal monitor. The electrode interface system of the invention preferably includes a conversion means for converting the signals from the electrode(s) into signals similar to those produced by a tocodynometer. | 05-12-2011 |
20110192398 | OBSTETRIC ANALGESIA SYSTEM - The present invention relates to systems and methods for providing a short-acting analgesic agent in the management of pain during labor, wherein the system enables efficient, real-time prediction of contractions for the coordinated administration of analgesia such that the peak effectiveness of the analgesic coincides with the intermittent pain of labor. | 08-11-2011 |
Dorothee Martin, Suresnes FR
Patent application number | Description | Published |
---|---|---|
20080269039 | Method of Refining Glass and Product Obtained - The subject of the invention is a method of refining glass for which the temperature (T log 2) corresponding to a viscosity of 100 poise (10 Pa·s) is greater than or equal to 1480° C., characterized in that sulfides are used as a refining agent. It also relates to the glass article capable of being obtained by this method. | 10-30-2008 |
20100069219 | METHOD OF REFINING A LITHIUM ALUMINOSILICATE GLASS AND GLASS-CERAMIC OBTAINED - The present invention relates to a method of refining lithium aluminosilicate glass capable of being controllably ceramized and free of arsenic oxide, antimony oxide and tin oxide, in which at least 0.05% by weight of at least one sulfide is added to the glass batch materials and said materials are melted at a temperature below 1750° C. | 03-18-2010 |
Dorothee Misse, Montpellier FR
Patent application number | Description | Published |
---|---|---|
20090062375 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES - The invention provides a method of treating viral haemorrhagic fevers, such as that caused by Dengue virus, which comprises administering a composition comprising a pharmaceutically active amount of a matrix metalloproteinase inhibitor. | 03-05-2009 |
Dorothee Quinzler, Alpnach Dorf CH
Patent application number | Description | Published |
---|---|---|
20130030075 | POLYMERS MADE OF RENEWABLE RESOURCES - Polycondensates with long-chain linear methylene sequences, their production, a method for producing linear odd-numbered C | 01-31-2013 |
Dorothee Sommer, Stuttgart DE
Patent application number | Description | Published |
---|---|---|
20100012096 | FUEL INJECTION DEVICE FOR AN INTERNAL COMBUSTION ENGINE - The fuel injection device for an internal combustion engine comprises a feed pump which has an electric drive, by which feed pump fuel is fed from a fuel storage tank into a low-pressure region to the suction side of at least one high-pressure pump. The high-pressure pump pumps fuel into a high-pressure region in which at least one injector is provided to inject the fuel into the internal combustion engine. The fuel injection is controlled by an electric control device. Arranged in the low-pressure region is a pressure sensor which is connected to the control device. The electric drive of the feed pump is activated by the control device in order to set a feed quantity of the feed pump which is variable as a function of at least one operating parameter of the internal combustion engine and/or of the high-pressure pump. The drive of the feed pump is in particular activated by the control device in such a way that, at a high load of the internal combustion engine and/or at a high rotational speed and/or at a high fuel temperature, a greater fuel quantity is fed by the feed pump into the low-pressure region than at a low load and/or a low rotational speed and/or a low fuel temperature. | 01-21-2010 |
20100307459 | METHOD AND DEVICE FOR CONTROLLING A FUEL-SUPPLY SYSTEM - In a method for controlling a fuel-supply system, a first supply unit supplies fuel from a storage container to a second supply unit. At least a partial quantity of the fuel quantity supplied by the first supply unit returns to the storage container as return quantity via a return line. The return quantity is determined as a function of the operating state of the fuel-supply system. The first supply unit is controlled at least as a function of the return quantity. | 12-09-2010 |
20120118268 | HIGH PRESSURE INJECTION SYSTEM HAVING FUEL COOLING FROM LOW PRESSURE REGION - The invention relates to a high pressure injection system having a fuel tank, a connection line between the fuel tank and a high pressure pump for sealing the fuel, wherein the high pressure pump is connected to at least one fuel injection valve via a corresponding connection line. According to the invention, at least a partial volume of the fuel sealed in the high pressure pump is fed back to the fuel tank from said fuel injection valve by leakage in the fuel injection valve via a return line connected to the fuel tank. An essential characteristic of the invention is that the high pressure injection system comprises a cooling line that connects the fuel tank or the low pressure region to the high pressure or a return of the high pressure pump via a mixing point with the return line. It is thereby possible to cool the fuel in the return lines between the fuel injection valve and the fuel tank. | 05-17-2012 |
Dorothee Stanneck, Solingen DE
Patent application number | Description | Published |
---|---|---|
20140294968 | POLYACRYLATE-BASED ACTIVE COMPOUND-COMPRISING PARTICLES - The invention relates to novel polyacrylate-based active compound-comprising particles which bind to hair, and to the use of these particles for preparing medicaments, in particular for veterinary medicine. The particles comprise uncharged and cationic polyacrylate and are at most 10 um big. | 10-02-2014 |
Dorothee Stirnweiss, Pommersfelden DE
Patent application number | Description | Published |
---|---|---|
20140152076 | WHEEL HUB DRIVE SYSTEM - A wheel hub drive system with an electric motor that can be arranged inside a wheel rim, whereby the electric motor is formed by rotor that is at least indirectly joined to a wheel hub and by means of a stationary stator that can be supplied with alternating current. With an eye towards obtaining more space for the vehicle occupants, it is proposed to arrange the converter with its entire power electronics unit on the stator so that the wheel hub drive system can be operated with direct current from the battery of the vehicle, or else no alternating current lines have to be laid in the vehicle. Consequently, the alternating current is generated by the converter that is arranged in a converter housing attached axially next to the stator. | 06-05-2014 |
Dorothee Viemann, Muenster DE
Patent application number | Description | Published |
---|---|---|
20110166059 | MEANS AND METHODS FOR EVALUATING A THERAPY WITH A P38 MAP KINASE INHIBITOR - The present invention relates to a method for determining whether therapy with a p38 MAP kinase inhibitor is potentially beneficial or potentially contraindicated for a subject suffering from a p38-mediated condition comprising measuring in a sample obtained from the subject the presence of at least one chromatin remodelling gene and/or of at least one pro-inflammatory gene, wherein the treatment is potentially beneficial for the subject, if at least one chromatin remodelling gene is underrepresented and/or at least one pro-inflammatory gene is overrepresented in comparison to a reference sample obtained from a subject not suffering from a p38-mediated condition; or wherein the treatment is potentially contraindicated for the subject, if at least one chromatin remodelling gene is overrepresented and/or at least one pro-inflammatory gene is underrepresented in comparison to a reference sample obtained from a subject not suffering from a p38-mediated condition. The present invention also relates to medical uses and methods of treatment applying a p38 MAP kinase inhibitor for treating a p38-mediated condition in a subject, wherein the patient is amenable to the treatment with the p38 MAP kinase inhibitor, if in the subject at least one chromatin remodelling gene is underrepresented and/or at least one pro-inflammatory gene is overrepresented in comparison to a reference sample obtained from a subject not suffering from a p38-mediated condition. Furthermore, a packaged medicament and a kit are provided comprising a p38 MAP kinase inhibitor or means for determining the presence of at least one chromatin remodelling gene and/or at least one pro-inflammatory gene in a sample from a subject suffering from a p38-mediated condition and instructions for use indicating that a subject suffering from a p38-mediated condition is amenable to the treatment with the p38 MAP kinase inhibitor, if it has been determined whether in said subject at least one chromatin remodelling gene is underrepresented and/or at least one pro-inflammatory gene is overrepresented in comparison to a reference sample obtained from a subject not suffering from a p38-mediated condition. | 07-07-2011 |